Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Follow-Up Questions
Vicapsys Life Sciences Inc のCEOは誰ですか？
Mr. Federico Pier は Vicapsys Life Sciences Inc の Chief Executive Officer で、2019 から在籍しています。
VICP の株価パフォーマンスは？
VICP の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Vicapsys Life Sciences Inc の主な事業テーマや業界は？
Vicapsys Life Sciences Inc は Biotechnology 業界、セクターは Health Care に属しています。
